Side effect profile and comparative tolerability of 21 antidepressants in the acute treatment of major depression in adults: protocol for a network meta-analysis. by Tomlinson, Anneka et al.
1 
 
Side effect profile and comparative tolerability of 21 
antidepressants in the acute treatment of major depression in 
adults: protocol for a network meta-analysis  
 
Anneka Tomlinson,1,2 Orestis Efthimiou,3 Katharine Boaden,2 Emma New,2 Sarah 
Mather,2 Georgia Salanti,3 Hissei Imai,4 Yusuke Ogawa,5 Aran Tajika,6 Sanae 
Kishimoto,4 Sino Kikuchi,4 Astrid Chevance,7,8 Toshi A Furukawa,4 Andrea Cipriani1,2  
 
1. Department of Psychiatry, University of Oxford, Oxford, UK 
2. Oxford Health NHS Foundation Trust, Warneford Hospital, Oxford, UK 
3. Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, 
Switzerland 
4. Department of Health Promotion and Human Behavior, Kyoto University Graduate 
School of Medicine/School of Public Health, Kyoto, Japan 
5. Department of Healthcare Epidemiology, Kyoto University Graduate School of 
Medicine/School of Public Health, Kyoto, Japan 
6. Department of Psychiatry, Kyoto University Hospital, Kyoto, Japan 
7. METHODS Team, Center for Research in Epidemiology and Statistics Sorbonne 
Paris Cité, Paris, France 
8. Paris Descartes University, Paris, France 
 
 
Correspondence to: 
 
Anneka Tomlinson 
Department of Psychiatry 
Warneford Hospital 
University of Oxford 
OX3 7JX, Oxford 
United Kingdom 
Email: anneka.tomlinson@psych.ox.ac.uk 
 
 
 
 
 
2 
 
Abstract  
 
Introduction  
We have recently compared all second-generation as well as selected first-
generation antidepressants in terms of efficacy and acceptability in the acute 
treatment of major depression. Here we present a protocol for a network meta-
analysis aimed at extending these results, updating the evidence base and 
comparing all second-generation as well as selected first-generation antidepressants 
in terms of specific adverse events and tolerability in the acute treatment of major 
depression in adults.  
 
Methods and analysis 
We will include all double-blind randomised controlled trials comparing one active 
drug with another or with placebo in the acute treatment major depression in adults. 
We will compare the following active agents: agomelatine, amitriptyline, bupropion, 
citalopram, clomipramine, desvenlafaxine, duloxetine, escitalopram, fluoxetine, 
fluvoxamine, levomilnacipran, milnacipran, mirtazapine, nefazodone, paroxetine, 
reboxetine, sertraline, trazodone, venlafaxine, vilazodone and vortioxetine. The main 
outcomes will include the total number of patients experiencing specific adverse 
events; experiencing serious adverse events; and experiencing at least one adverse 
event. Published and unpublished studies will be retrieved through relevant database 
searches, trial registries and websites; reference selection and data extraction will be 
completed by at least two independent reviewers. For each outcome we will 
undertake a network meta-analysis to synthesise all evidence. We will use local and 
global methods to evaluate consistency. We will perform all analyses in R. We will 
assess the quality of evidence contributing to network estimates with the CiNeMA 
(Confidence in Network Meta-Analysis) web application.  
 
Ethics and dissemination: This review does not require ethical approval.  
 
PROSPERO registration number: CRD42019128141.   
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Background 
Depression affects 350 million people worldwide and it is the second leading cause 
of global disease burden .1 The high direct and indirect costs for major depression 
are substantially due to significant deficits in treatment provision. There are a 
number of efficacious pharmacological and non-pharmacological interventions for 
depression, however a significant proportion of patients with major depression 
remain inadequately treated. Antidepressants are widely prescribed across the world 
in both primary and secondary care; however, poor adherence and premature 
discontinuation of antidepressant medication contribute to suboptimal clinical 
outcomes. Up to one third of patients discontinue antidepressants due to adverse 
effects and this is a major barrier to antidepressant treatment.  
 
Our recent GRISELDA project (Group of Researchers Investigating Specific Efficacy 
of individual Drugs for Acute depression) reported that the acceptability of 
antidepressants and drop-outs due to adverse events vary between drugs and the 
withdrawal rates tend to be higher than placebo.2 This current network meta-analysis 
(NMA) is the completion of the GRISELDA project and is based on the same 
protocol (that have the same PROSPERO registration number, CRD42019128141).3 
We have designed this NMA to investigate the profile of specific adverse events for 
each antidepressants. This will contribute to a better understanding of how to use 
antidepressants in the treatment of depression in adults. .4  
 
The objective of this NMA is to compare the specific side effects and the overall 
tolerability of all second-generation antidepressants and selected first-generation 
antidepressants in the acute treatment of major depressive disorder in adults. The 
project is called Meta-Analysis of Relative Tolerability and Harms of Antidepressants 
(MARTHA).  
 
Methods and analysis  
Types of studies  
We will include double-blind RCTs comparing one active drug with another or with 
placebo, as monotherapy, in the acute phase treatment of major depression. Cross-
over and cluster randomised trials will be included, while quasi-randomised trials will 
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be excluded. For cross-over studies, to address concerns around possible ‘carry 
over’ effects, we will use data from the pre-crossover phase.3 
 
Types of participants  
Patients aged 18 years or older, of both sexes, with a primary diagnosis of unipolar 
major depression according to standard operationalised diagnostic criteria, such as 
Feighner criteria, Research Diagnostic Criteria, DSM-III, DSM-III-R, DSM-IV, DSM-5, 
ICD-10 and ICD-11, will be included. Studies in which 20% or more of the 
participants may be suffering from bipolar or psychotic depression will be excluded. 
A concurrent secondary diagnosis of another psychiatric disorder will not be 
considered as exclusion criterion, but RCTs in which all participants have a 
concurrent primary diagnosis of another mental disorder or concomitant medical 
disorder will be excluded. Antidepressant trials in depressive patients with a serious 
concomitant medical illness, post-partum or treatment resistant depression will be 
excluded.  
 
Types of interventions  
We will include the following antidepressants: agomelatine, amitriptyline, bupropion, 
citalopram, clomipramine, desvenlafaxine, duloxetine, escitalopram, fluoxetine, 
fluvoxamine, levomilnacipran, milnacipran, mirtazapine, nefazodone, paroxetine, 
reboxetine, sertraline, trazodone, venlafaxine, vilazodone and vortioxetine (see 
GRISELDA protocol for more detail).3 Rescue medications will be allowed if equally 
provided among the randomised arms. We will include only studies randomising 
patients to drugs within their licensed dose range.3,5 We anticipate that any patient 
who meets all inclusion criteria could, in principle, be randomised to receive any of 
the interventions in the synthesis comparator set (assumption of transitivity). 
 
Outcome measures and categorisation of adverse events 
Tolerability will be evaluated using the following outcome measures: 
1. Total number of patients experiencing one specific adverse event; 
2. Total number of patients experiencing serious adverse events; 
3. Total number of patients experiencing at least one adverse event. 
 
5 
 
Two independent researchers will extract all adverse effects reported in the trials 
(paying careful attention not to double count events) and will then use preferred 
terms from MedDRA (https://www.meddra.org/) to categorise each adverse event. 
MedDRA has been developed by the International Council for Harmonisation of 
Technical Requirements for Pharmaceuticals for Human Use to provide a single 
standardised international medical terminology which can be used for regulatory 
communication and evaluation of data pertaining to medicinal products for human 
use. As a result, MedDRA is designed for use in the registration, documentation and 
safety monitoring of medicinal products through all phases of the development cycle 
(i.e., from clinical trials to post-marketing surveillance).  
There are five levels to the MedDRA hierarchy, arranged from very specific to very 
general. At the most specific level, called “Lowest Level Terms” (LLTs), there are 
more than 70,000 terms which parallel how information is communicated. These 
LLTs reflect how an observation might be reported in practice (i.e. in a specific 
study). This level directly supports assigning MedDRA terms within a user database. 
Each member of the next level, “Preferred Terms” (PTs), is a distinct descriptor 
(single medical concept) for a symptom, sign or disease diagnosis. Each LLT is 
linked to only one PT and each PT has at least one LLT (itself) as well as synonyms 
and lexical variants (e.g., abbreviations, different word order). If we find different 
MedDRA terms to identify similar adverse events, these synonyms will be merged 
using clinical judgement into broader categories (as applicable) and validated by 
another clinician. Any discrepancies will be solved by consensus within the review 
team. 
 
To define serious adverse events, we will use the classification employed by the US 
Food and Drug Administration (https://www.fda.gov/):   
• results in death, or 
• is life-threatening, or 
• requires inpatient hospitalisation or causes prolongation of existing 
hospitalisation, or  
• results in persistent or significant disability/incapacity, or 
• may have caused a congenital anomaly/birth defect, or 
• requires intervention to prevent permanent impairment or damage. 
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All serious adverse effects will be included in the meta-analysis. 
 
Common and very common adverse events 
We will also identify common and very common non-serious adverse events using 
the approved definition of frequency of adverse event issued by the Council of 
International Organizations of Medical Sciences:  
 
Type of adverse event Frequency 
Very common ≥10% 
Common ≥1% and <10% 
Uncommon ≥0.1% and <1% 
Rare or very rare <0.1% 
 
If the number of common and very common adverse effect is over 20, a survey 
including patients and clinicians’ perspective will be carried out to select which 
adverse effects should be considered for use in the in the statistical analyses. 
 
Survey 
We will include two types of participants:  
• Patients: any individual over 18 years old with a current/previous episode of 
unipolar depression and current/previous use of antidepressants.  
• Prescribing clinicians: any healthcare professional (psychiatrist, general 
practitioner, prescribing nurse or prescribing pharmacist) with personal 
experience in prescribing and monitoring antidepressants in depression.    
 
The questionnaire will be in English, French and German. We aim to recruit at least 
200 patients and 100 physicians from multiple countries to increase the external 
validity of the findings.  
 
The survey will collect data about the following aspects: 
 
1) Sociodemographic characteristics and health status of participants:  
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For patients: sex, age, country of residency, number of years of education, income, 
PHQ-9, diagnosis, setting of care, number and names of antidepressants ever taken, 
duration of treatment, suicidal behaviour, length of current episode, total length of 
exposure to antidepressants. 
For prescribing clinicians: sex, age, country of practice, profession, duration of 
clinical experience, workplace, personal experience of depression/antidepressants. 
 
2) Ranking of the adverse events  
Each participant will be asked to rank the adverse event according to their personal 
preference. The list presented to patients will contain only clinical adverse events 
that can be understood by lay people, whereas the list of adverse events for 
clinicians will also include biological measures (for instance, liver function or glucose 
blood levels). For patients, we will use the specific “patient-friendly” wording of 
MedDRA and for clinicians the MedDRA terminology. 
 
 A modified Q-sort method will be used to rank the adverse events and the final list of 
adverse events will include all of the serious adverse events plus the 20 most 
important non-serious adverse events. If appropriate, the researchers will review the 
lists of adverse events generated from the survey and include any further adverse 
events considered to be clinically relevant. 
 
Search strategy and study selection  
We will use the same search strategy that we used before for GRISELDA3 and 
perform an update of the search. The reference selection process will be done by 
two researchers independently. Any disagreements will be resolved via discussion 
with a third member of the review team. 
 
Data extraction  
Two reviewers will independently extract from the included studies the relevant 
information about specific adverse events using a predefined structured template. 
Any discrepancies will be discussed between the two reviewers and any unresolved 
discrepancies will be resolved by a third senior reviewer. When different values are 
provided in the published and unpublished studies, the unpublished data will be 
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prioritised and extracted. Two review authors will ascertain that the data are entered 
correctly into the final data set.  
 
Length of trial  
We will consider the number of participants with adverse events in each treatment 
arm at 8 weeks.5 If information at 8 weeks is not available, we will use data ranging 
between 4 and 12 weeks (we will give preference to the timepoint closest to 8 
weeks; if equidistant, we will take the longer outcome). Longer term studies will be 
included in the systematic review but excluded from the statistical synthesis of data if 
they do not provide data for the 4–12 weeks period.  
 
Comparability of dosages 
We will include only study arms randomising patients to drugs within the licensed 
dose. Both fixed-dose and flexible-dose designs will be allowed.  
 
Risk of bias assessment  
We will assess risk of bias in the included studies using the tool described in the 
Cochrane Collaboration Handbook as a reference guide (http://handbook-5-
1.cochrane.org/). The assessment will be performed by two independent raters. If 
the raters disagree, the final rating will be made by consensus with the involvement 
(if necessary) of another member of the review group. 
 
Statistical synthesis of study data  
We will generate descriptive statistics for the trial, and study population 
characteristics across all eligible trials, describing the types of comparisons and 
some important variables, either clinical or methodological (such as year of 
publication, age, severity of illness, sponsorship   and clinical setting). We will draw 
the network diagram to graphically present the available evidence.  
 
Pairwise meta-analyses 
For each pairwise comparison in the dataset that is informed by 10 studies or more, 
we will synthesize data using a random effects meta-analysis model, to obtain ORs 
and 95% Confidence Intervals (CIs). This model assumes that true underlying 
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treatment effects are similar, but not identical across the different study settings, and 
allows us to estimate heterogeneity.  
 
One complication we expect to face is that for many specific adverse events 
we may have low or very low event rates in our dataset. When the outcome is 
rare, i.e. when there are studies with zero arms in one or both treatment arms, 
the inverse-variance method for meta-analysis might lead to biased results 
(https://training.cochrane.org/handbook/version-6/chapter-10-draft). In such cases 
we will also use the Mantel-Haenszel method to synthesize the evidence.6 This 
model avoids the use of the so-called ‘continuity correction’, which artificially 
imputes data and might bias results. The model assumes a common (fixed) 
treatment effect, i.e. does not include heterogeneity. This is a limitation of the 
approach, but, as the Cochrane Handbook suggests, incorporation of 
heterogeneity should be a secondary consideration when attempting to 
estimate treatment effects from sparse data 
(https://training.cochrane.org/handbook/version-6/chapter-10-draft). In order to 
decide which method to use as our primary analysis for rare outcomes, we will 
fit a fixed-effects inverse-variance and a Mantel-Haenszel model, and compare 
results. If the two approaches provide similar results, we will conclude that the 
continuity corrections have minimal effect on the results of the inverse-
variance method. In that case, we will employ a random-effects inverse-
variance model as our primary analysis. If there are important discrepancies 
between the two approaches, we will only use the Mantel-Haenszel method.  
 
Furthermore, when data are rare, the choice of model becomes important,7 
and different models might give substantially different results. Thus, for the five 
most important rare outcomes according to our ranking, we will employ 
additional models (Peto odds ratio, a Bayesian meta-analysis model with 
informative prior distributions for heterogeneity8 and a beta-binomial model, as 
seen fit according to the assumptions of the different models).7 This will allow 
us to assess the robustness of our findings under different model choices. If 
different models lead to substantially different results, we will present all 
results on equal grounds and we will refrain from drawing firm conclusions 
regarding relative treatment effects.   
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For all pairwise meta-analyses we will present forest plots. We will use a 0.5 
continuity correction, in order to present in the plots studies with zero events in one 
of their arms. For studies with zero events in both arms we will not show any relative 
effects.  
 
We will visually inspect the forest plots to identify any particularly heterogeneous 
comparisons. For the analyses where random effects model will be used, we will 
compare the estimated standard deviation of random effects with the corresponding 
empirical distribution.8 We will also report the I2 statistic and its 95% CI, as an 
additional measure of heterogeneity in the pairwise meta-analyses.  
 
Assessment of the transitivity assumption of NMA 
The key underlying assumption of NMA is the assumption of transitivity.9,10 In order 
to assess the validity of this assumption, we will investigate whether study-level 
characteristics that may impact on the relative treatment effects (i.e. effect modifiers) 
are similarly distributed across treatment comparisons. Potential effect modifiers 
include clinical and demographic characteristics, such as age, gender, dose and 
severity of symptoms. We will group studies by treatment comparisons and obtain 
descriptive statistics regarding these important covariates. In case we find significant 
discrepancies in the corresponding distributions, we will limit our network meta-
analyses to studies that are sufficiently similar.  
 
The clinical features, which have been demonstrated to date to moderate 
efficacy of antidepressants include bipolarity,11 psychotic features,12 and 
subthreshold depression.13 We have assured transitivity in our network with 
regard to these variables by limiting our samples to participants with non-
psychotic unipolar major depression. Other clinical or methodological variables 
that may influence our primary outcomes of antidepressant efficacy or 
acceptability include: age,14 depressive severity at baseline15 and the dosing 
schedule.16 We will investigate if these variables are similarly distributed across 
studies grouped by comparison.  
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Network meta-analyses 
If we find no evidence against the transitivity assumption, we will synthesize the 
evidence using NMA.10 For non-rare outcomes we will use a random-effects NMA 
model17 fit in a frequentist setting, assuming a common heterogeneity parameter 
across all treatment comparisons. We will present the ‘league-table’ of results, i.e. a 
table with all estimated treatment effects and the corresponding 95% CIs. For each 
outcome, in order to assess the extent of heterogeneity, we will compare the 
estimated value for the heterogeneity standard deviation with the corresponding 
empirical distributions.8 In addition, we will present the prediction intervals for each 
drug vs. placebo; this will allow us to gauge the effect of heterogeneity in the true 
underlying treatment effects of a future study. We will rank the various treatments for 
each outcome using the surface under the cumulative ranking curve (SUCRA).18 
 
For rare outcomes, i.e. when there are studies with zero events in some of their 
treatment arms, we will perform a NMA using a fixed-effects Mantel-Haenszel NMA 
approach19 and compare results with the fixed-effects inverse-variance NMA model. If 
results agree, we will use the random-effects NMA model as our primary analysis.17 If 
we find important discrepancies we will only present results from the Mantel-Haenszel 
NMA approach. In sensitivity analyses we will also employ a NMA model with a non-
central hypergeometric (NCH) likelihood.20 Both Mantel-Haenszel and NCH NMA can 
handle studies with zero events in one (but not all) of their treatment arms; in 
simulations we have shown that these two models perform well under sparse data 
settings. Notably, both models exclude studies with zero events in all treatment arms. 
Thus, for very rare outcomes, we expect that the network might become disconnected. 
In that case we will perform NMAs in each of the corresponding sub-networks that 
include enough data to be meaningfully synthesized.  
 
For some specific outcomes (i.e. gastrointestinal side effects, neurological symptoms, 
etc) we assume that the relative treatment effects of the various drugs vs. placebo are 
exchangeable, i.e. they follow an underlying common distribution. This is based on the 
assumption that the different drugs might have similar pathways to the outcome. For 
these outcomes, we will employ a Bayesian, multi-level hierarchical NMA model that 
assumes exchangeability of the treatment effects against a common comparator. This 
model has been shown both theoretically and in simulations to lead to an increase of 
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the statistical power to detect treatment effects of drugs vs. placebo, while 
automatically controlling for the possibility of multiple testing issues.21   
 
Assessment of inconsistency 
Inconsistency corresponds to the (statistical) disagreement between the different 
sources of evidence in a network.10 Assessment of inconsistency is an important part 
of NMA. It offers an additional, quantitative method of exploring the validity of 
transitivity assumption.9 Large inconsistency implies a breach of transitivity, which in 
turn suggests that synthesizing data in a NMA should be avoided.  
 
We will use two different methods for assessing inconsistency in the network. The 
first one is a ‘global’ method, the design-by-treatment test.22 This is a test against the 
null hypothesis of overall consistency in the network. Subsequently, we will employ a 
‘local’ method, ‘Separate Indirect from Direct Design Evidence’ (SIDDE).19 Using 
SIDDE, we group the studies by design (i.e. according to the group of treatments 
they compare). Then, for each treatment comparison in each design we estimate the 
direct evidence (from studies of this particular design) and indirect evidence (from 
the rest of the network). We then compare the two estimates; important differences 
will point to hotspots of inconsistency in the network.  
 
If these methods suggest the presence of important inconsistency in the network, we 
will first try to scan our data for extraction errors. If none is found, we will revisit the 
studies to assess again the plausibility of the transitivity assumption, especially if 
some hotspots of inconsistency are identified using the SIDDE approach. If we 
identify possible reasons for this inconsistency we will account for it by performing 
subgroup analyses. If we cannot identify the cause of inconsistency, we will refrain 
from performing a NMA. 
 
All methods for inconsistency, however, are expected to have low power in detecting 
breaches of the transitivity assumption. Especially for the case of rare outcomes 
(which we expect to have in our analyses), all tests for inconsistency are expected to 
be extremely low powered. In addition, absence of a statistically significant result in 
tests for inconsistency does not offer proof of transitivity. Thus, we aim to perform a 
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thorough assessment of transitivity even in the absence of any proof of 
inconsistency.  
 
Exploring heterogeneity and inconsistency and sensitivity analyses 
We expect small amounts of heterogeneity and inconsistency to be present given the 
variety of study settings we plan to include. For the most common adverse events, 
we will explore whether treatment effects are robust in subgroup analyses and 
network meta-regression using the following characteristics: (1) study year; (2) 
sponsorship; (3) depressive severity at baseline; (4) dosing schedule; (5) head-to-
head vs placebo controlled studies; (6) single-centre vs multi-centre studies).1The 
sensitivity of our conclusions will be evaluated by analysing (1) only studies with 
balanced doses in all arms (i.e., we will exclude studies with unfair dose 
comparisons); (2) only studies with unpublished data (i.e., we will exclude studies 
providing published data only); (3) only studies with low risk of bias; (4) only head-to-
head studies.  
 
Assessing small study effects, publication bias, reporting bias 
It has been empirically shown that safety outcomes are in high risk of reporting 
bias,23 and that trials tend to systematically understate adverse events.24 This 
phenomenon might be more pronounced in placebo-controlled trials.2 In order to 
assess the existence of small-study effects and publication biases, we will use funnel 
plots and contour-enhanced funnel-plots.25 This will allow us to check whether the 
precision of the studies (which is directly related to sample size) correlates with the 
effect size. We will use the Harbord test26 to formally test for asymmetries in the 
funnel plots. We will follow this procedure for pairwise comparisons between 
antidepressant and placebo. If we identify an important association of the reported 
effect with the trials’ precision, we will try to adjust for it in a sensitivity analysis, by 
performing a network meta-regression with the trial precision as a study-level 
covariate. If there is strong evidence of small study effects or publication bias, we will 
clearly report it and interpret all results with caution.  
 
Model implementation 
We will fit all models in R. We will fit the pairwise meta-analysis models using the 
meta package.27 All frequentist NMAs will be fit using the netmeta package.28 We will 
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perform all Bayesian analyses using the R2jags packages.29 For all Bayesian models 
we will assume a binomial likelihood for the number of events per treatment arm. We 
will employ uninformative prior distributions, e.g. 𝑁𝑁(0,1002) for all location parameters 
such as the log-odds ratios of relative treatment effects. For the heterogeneity 
parameter we will employ the empirical distributions described elsewhere.8 We will run 
multiple chains and assess convergence and mixing of the chains using the Brooks-
Gelman-Rubin diagnostic criterion. 
 
Assessing the confidence of evidence of NMA 
The quality of evidence obtained by the synthesis of the evidence for each outcome 
will be separately evaluated using the framework described in Salanti et al.30 and 
implemented using the CINeMA31 (Confidence in Network Meta-Analysis) web 
application. This will allows to grade the confidence in the results into high, 
moderate, low or very low.  
 
Discussion  
The adverse effects of the antidepressants and their perceived marginal efficacy are 
major factors contributing to the unsatisfactory treatment duration of antidepressants. 
These factors are exacerbated by our current inability to predict which drug will 
causes the fewest adverse effects for a specific patient, and which will work most 
effectively. This work will provide an in-depth analysis and an insight into the specific 
adverse events of individual antidepressants. This NMA is a key step in retrieving 
and understanding all of the information needed to guide the shared decision-making 
process between patients, carers, and clinicians.  It has been widely reported and 
recognised in the scientific literature.32 Matching patients to individual 
antidepressants, this will enable clinicians to precisely customise treatment to 
patients’ needs and thus improve their outcome.  
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